Published online before print November 7, 2002, doi: 10.1161/01.ATV.0000046235.22451.66
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2002 American Heart Association, Inc.
Thrombosis |
Thrombospondin-2 Polymorphism Is Associated With a Reduced Risk of Premature Myocardial Infarction
From the Departments of Cardiology (S.M.B., M.D.T., R.J.G.P., M.E.), Clinical Epidemiology and Biostatistics (A.H.Z.), and Vascular Medicine (J.J.P.K.) and Laboratory for Experimental Internal Medicine (P.H.R.), Academic Medical Center, Amsterdam and the Department of Chronic Disease Epidemiology (J.M.A.B., E.J.M.F.), National Institute of Public Health and the Environment, Bilthoven, The Netherlands.
Correspondence to S.M. Boekholdt, MD, Academic Medical Center, Department of Cardiology, Room F3-241, PO Box 22660, 1100 DD, Amsterdam, The Netherlands. E-mail s.m.boekholdt{at}amc.uva.nl
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Objective— Recently, polymorphisms in thrombospondin (THBS) genes coding for THBS-1 (N700S), THBS-2 (T>G substitution in 3'-untranslated region), and THBS-4 (A387P) genes were proposed to modulate the risk of premature coronary artery disease (CAD) or myocardial infarction (MI). It was our objective to verify this hypothesis in an independent cohort.
Methods and Results— We performed a case-control study among patients (n=503) referred to our institution for symptomatic CAD that occurred before the age of 50 years and a group of age- and sex-matched population-based controls free of CAD (n=1071). The THBS-1 variant allele was not associated with an altered risk of premature CAD or MI. Homozygosity for the THBS-2 variant allele and the THBS-4 variant (387P) allele was significantly associated with a reduced risk of premature MI compared with wild-type individuals (OR=0.44, 0.24 to 0.84 and OR=0.43, 0.22 to 0.85, respectively). The latter observation is in contrast with a previous report, although confidence intervals overlap.
Conclusions— We conclude that a relationship between the THBS-1 N700S polymorphism and premature CAD is unlikely. For the THBS-4 A387P polymorphism, additional studies are required to elucidate its role in premature CAD. Finally, we conclude that the THBS-2 polymorphism is associated with a reduced risk of premature MI.
Key Words: thrombospondin • polymorphism • premature coronary artery disease • premature myocardial infarction
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Thrombospondins form a family of multidomain extracellular matrix proteins with related sequences but diverse tissue distributions. They are involved in a wide range of processes in the vessel wall, including smooth muscle cell proliferation,1 endothelial cell proliferation, and migratio,2 and they bind to various extracellular matrix proteins.3 Therefore, variations in the genes coding for these proteins are potential risk factors for premature coronary artery disease (CAD). Recently, an exploratory genetic association study called GeneQuest tested 72 single nucleotide polymorphisms and identified 3 polymorphisms in thrombospondin-1, -2, and -4 (THBS-1, -2, and -4, respectively) to potentially modulate the risk of premature CAD or myocardial infarction (MI). These polymorphisms were an A>G substitution at position 8831 of the THBS-1 gene (located on chromosome 15q15), predicting an asparagine to serine substitution at position 700 (N700S); a T>G substitution in the 3'-untranslated region (3'UTR) of the THBS-2 gene, which is located on chromosome 6q27; and a G>C substitution at position 29926 of the THBS-4 gene (located on chromosome 5q13), predicting an alanine to proline substitution at position 387 (A387P).4 However, this exploratory study design testing numerous hypotheses is prone to false-positive findings. Therefore, the findings require independent replication in other population samples. We tested the hypothesis in a larger group of individuals with CAD that occurred before the age of 50 years.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Design and Study Sample
Cases (n=503) were consecutive, unrelated individuals referred to the Academic Medical Center in Amsterdam for symptomatic CAD that occurred before the age of 50 years. Patients qualified for inclusion after an MI (according to World Health Organization criteria, n=320), surgical or percutaneous coronary revascularization, or a coronary angiogram with evidence of at least 70% stenosis in a major epicardial artery. The protocol was approved by our Institutional Review Board. Control subjects (n=1071) were selected from the participants of the Cardiovascular Disease Risk Factor Monitoring Project, a large screening project for cardiovascular risk factors.5 Approximately 2 control subjects per case were selected, group-matched for sex and age (within 5 years). All controls had the Dutch nationality and reported no history of CAD in a self-administered questionnaire. All patients and control subjects gave informed consent.
Laboratory Procedures
Nonfasting blood samples were obtained in EDTA-coated Vacutainer tubes. Genomic DNA was extracted according to a standard protocol. Polymerase chain reaction (PCR) amplification was performed on 1 µL DNA in 10 µL ReddyMix (ABgene).
For THBS-1, the following primers were used: forward: GCATGGTGTACCCTCAGGTG; reverse: TGTTTTGATAAGGTGATGGGC. PCR products were 293 bp, and digestion with BsrI restriction enzyme (3 hours, 65°C) generated 2 additional fragments of 191 and 102 bp in the presence of the G allele. For THBS-2, the following primers were used: forward: CTGT GCATGCCATGGTCCCTAGA; reverse: TATCATAATGGCTTATGCACAGTATTCCCT TCA. PCR products were 363 bp, and digestion with DdeI restriction enzyme (12 hours, 37°C) generated 3 fragments of 27, 134, and 202 bp in the presence of the T allele and an additional 336-bp band in the presence of the G allele. For THBS-4, the following primers were used: forward: ATATTATGCCCACATGTTCTAG; reverse: CCTCAGATTACCAT TCTACCCG. PCR products were 310 bp, and digestion with Cac8I (12 hours, 37°C) generated 2 fragments of 142 and 168 bp in the presence of the G allele and an additional band at 310 bp in the presence of a C allele. All restriction enzymes were obtained from New England Biolabs. The digest was analyzed by electrophoresis in a 2% agarose gel.
Plasma samples were obtained in citrate-coated Vacutainer tubes and stored at -80°C. Western blotting for the detection of THBS-2 in plasma was performed as previously described with minor modifications.6 The antibody was obtained from Becton Dickinson Biosciences.
Researchers and laboratory personnel had no access to identifiable information and could identify samples by a number only.
Statistical Analysis
Sample size calculations were based on the GeneQuest findings using the polymorphism with the strongest association (THBS-4). We expected similar allele frequencies in our subjects and aimed at including 500 patients and 1000 controls to have 80% power. For each polymorphism, risk factors were compared between wild-type individuals, heterozygotes, and homozygotes for the variant allele and also between noncarriers and carriers of the variant allele. These results did not differ importantly, and, thus, for the sake of brevity, only comparisons between carriers and noncarriers are presented. Differences between groups were assessed with a Fisher’s exact test, t test, Mann-Whitney test, or Kruskal-Wallis test, where appropriate. Odds ratios (ORs) and associated 95% confidence intervals (95% CI) were calculated to quantify the risk of premature CAD and premature MI for carriers and homozygotes of the variant allele compared with wild-type individuals. ORs were adjusted for sex, total cholesterol, hypertension, diabetes, and smoking.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The average ages of cases and controls were 40±6 and 39±7 years, respectively, and percentages of males were 81% and 76%, respectively. Cases and controls differed significantly for the risk factors smoking, hypertension, diabetes, body mass index, total cholesterol, and HDL (P<0.0001 for each) (Table 1). Genotyping for the THBS-1, THBS-2, and THBS-4 polymorphisms was successful in 97.2%, 96.3%, and 93.4%. The genotype distributions for the THBS polymorphisms are presented in Table 2. Both cases and controls were in Hardy-Weinberg equilibrium for all 3 polymorphisms.
|
|
The major risk factors were equally distributed in carriers (heterozygotes+variant homozygotes) and wild-type individuals, except for a small difference in triglycerides between THBS-4 carriers and wild-type individuals. Compared with wild-type individuals, carriers of the THBS-1 variant allele were not at increased risk for having premature CAD (OR=0.93, 0.74 to 1.31) or MI (OR=0.89, 0.66 to 1.24). Homozygotes for the THBS-2 rare allele did have a lower risk of premature CAD on the edge of significance (OR=0.58, 0.33 to 0.99) but a strongly significantly lower risk of premature MI (OR=0.44, 0.24 to 0.84). Similarly, homozygosity for the THBS-4 variant allele had a weakly significant association with a lower risk of premature CAD (OR=0.51, 0.28 to 0.94), but a strongly significant association was observed with a lower risk of premature MI (OR=0.43, 0.22 to 0.85). Correcting for 6 independent hypotheses (3 genes tested for 2 outcomes) resulted in none of the associations reaching P<0.05.
In an attempt to provide supporting evidence for the observed genotype-disease relationship for THBS-2, we set out to determine THBS-2 plasma levels as an intermediate phenotype. However, the detection of THBS-2 in human plasma has never been published. We performed Western blotting on stored human plasma samples of patients included in the study but could not detect THBS-2 in these samples.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
We found that the recently reported THBS-1 N700S polymorphism was not significantly associated with premature CAD or MI in our sample. Homozygosity for the THBS-2 variant allele was significantly associated with a lower risk of premature MI, which is in accordance with the GeneQuest findings. Homozygosity for the THBS-4 variant 387P allele was also associated with a reduced risk of premature MI, which contradicts the GeneQuest result.
In recent years, numerous studies have proposed genetic variations as risk factors for cardiovascular disease but only few candidates have consistently passed the test of replication.7 In fact, the GeneQuest investigators report that they could not replicate their findings for the THBS-4 A387P polymorphism in 2 smaller samples.4 The discrepancy between the GeneQuest results and ours may be accounted for by intrinsic differences between the population samples. However, adjustment for traditional cardiovascular risk factors did not substantially affect the results. In addition, several biases and confounders can affect the results of genetic association studies and may account for the discrepant results.8 In this journal, Hegele9 recently discussed the pros and cons of genetic association studies and proposed several desirable attributes. Our study design incorporated several characteristics to minimize the effect of potential errors and confounders. Both the GeneQuest study and ours had strict criteria that were very similar although not identical. Inclusion in GeneQuest required that at least one sibling of the proband also fulfilled the criteria for premature CAD, a requirement not used in our study. However, in our sample, a positive family history for premature CAD was equally distributed among all genotypes. An important difference between the studies is that unlike GeneQuest, our control group was matched to the cases by age, sex, and ethnicity to avoid genetic admixture. Finally, our study included more patients and more controls than the GeneQuest study. However, several limitations remain. To investigate the functionality of this polymorphism, we attempted to determine THBS-2 plasma levels. We could not detect any THBS-2 in human plasma, which is consistent with the observation that unlike THBS-1, THBS-2 is not in present in platelets and is not synthesized by cultured mouse endothelial cells.10 Thus, our report does not provide data on the potential functionality of the THBS-2 polymorphism. Conceivably, the polymorphism is associated with an altered local expression pattern in the vessel wall after injury. Because of the absence of a biochemical intermediate phenotype, research to test this hypothesis would require animal models. Second, the present study describes a single patient sample. The very strict inclusion criteria necessitate either an extensive multicenter design, as in the GeneQuest study, or a very long inclusion period, as in ours. Therefore, the number of large, similarly defined patient samples is most likely limited.
The mechanism by which THBS-2 affects atherosclerosis may involve the regulation of matrix metalloproteinase-2, a protein linked to the vulnerability of atherosclerotic plaque. THBS2-null fibroblasts produce a 2-fold quantity of this protein,11 which was shown to be lower in CAD patients than in controls.12 Alternatively, THBS-2–deficient mice have an increased vascular density and a bleeding tendency, which can both be hypothesized to reduce the risk of MI.6 We conclude that for the THBS-1 N700S and the THBS-4 A387P polymorphisms, a role as genetic risk factor for premature CAD is unlikely. In addition, we conclude that the THBS-2 3'UTR polymorphism is associated with a reduced risk of premature MI. Additional research into the functionality of this polymorphism is warranted.
|
Acknowledgments |
|---|
Dr Boer was funded by the Netherlands Heart Foundation (No. 98.067). We gratefully acknowledge P. Bornstein, MD (University of Washington, Seattle, Wash), for his helpful suggestions.
Received September 5, 2002; accepted November 17, 2002.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Majack RA, Cook SC, Bornstein P. Control of smooth muscle cell growth by components of the extracellular matrix: autocrine role for thrombospondin. Proc Natl Acad Sci U S A. 1986; 83: 9050–9054.
2. Taraboletti G, Roberts D, Liotta LA, Giavazzi R. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol. 1990; 111: 765–772.
3. Narouz-Ott L, Maurer P, Nitsche DP, Smyth N, Paulsson M. Thrombospondin-4 binds specifically to both collagenous and non-collagenous extracellular matrix proteins via its C-terminal domains. J Biol Chem. 2000; 275: 37110–37117.
4. Topol EJ, McCarthy J, Gabriel S, Moliterno DJ, Rogers WJ, Newby LK, Freedman M, Metivier J, Cannata R, O’Donnell CJ, Kottke-Merchant K, Murugesan G, Plow EF, Stenina O, Daley GQ, for the GeneQuest investigators and collaborators. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation. 2001; 104: 2641–2644.
5. Verschuren WMM, van Leer EM, Blokstra A, Seidell JC, Smit HA, Bueno de Mosquita HB, Obermann-de Boer GL, Kromhout D. Cardiovascular disease risk factors in the Netherlands. Neth J Cardiol. 1993; 6: 205–210.
6. Kyriakides TR, Zhu YH, Smith LT, Bain SD, Yang Z, Lin MT, Danielson KG, Iozzo RV, LaMarca M, McKinney CE, Ginns EI, Bornstein P. Mice that lack thrombospondin 2 display connective tissue abnormalities that are associated with disordered collagen fibrillogenesis, an increased vascular density, and a bleeding diathesis. J Cell Biol. 1998; 140: 419–430.
7. Ioannidis JPA, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet. 2001; 29: 306–309.[CrossRef][Medline] [Order article via Infotrieve]
8. Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors in complex diseases. Lancet. 2001; 358: 1356–1360.[CrossRef][Medline] [Order article via Infotrieve]
9. Hegele RA. SNP judgments and freedom of association. Arterioscler Thromb Vasc Biol. 2002; 22: 1058–1061.
10. Armstrong LC, Bjorkblom B, Hankenson KD, Siadak AW, Stiles CE, Bornstein P. Thrombospondin 2 inhibits microvascular endothelial cell proliferation by a caspase-independent mechanism. Mol Biol Cell. 2002; 13: 1893–1905.
11. Yang Z, Kyriakides TR, Bornstein P. Matricellular proteins as modulators of cell-matrix interactions: adhesive defect in thrombospondin 2-null fibroblasts is a consequence of increased levels of matrix metalloproteinase-2. Mol Biol Cell. 2000; 11: 3353–3364.
12. Noji Y, Kajinami K, Kawashiri MA, Todo Y, Horita T, Nohara A, Higashikata T, Inazu A, Koizumi J, Takegoshi T, Mabuchi H. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med. 2001; 39: 380–384.[CrossRef][Medline] [Order article via Infotrieve]
This article has been cited by other articles:
 |
|
 |
|
  W. Koch, P. Hoppmann, A. de Waha, A. Schomig, and A. Kastrati Polymorphisms in thrombospondin genes and myocardial infarction: a case-control study and a meta-analysis of available evidence Hum. Mol. Genet., April 15, 2008; 17(8): 1120 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Damani and E. J. Topol Future Use of Genomics in Coronary Artery Disease J. Am. Coll. Cardiol., November 13, 2007; 50(20): 1933 - 1940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. I. Stenina, E. J. Topol, and E. F. Plow Thrombospondins, Their Polymorphisms, and Cardiovascular Disease Arterioscler. Thromb. Vasc. Biol., September 1, 2007; 27(9): 1886 - 1894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. M. Morgan, H. M. Krumholz, R. P. Lifton, and J. A. Spertus Nonvalidation of Reported Genetic Risk Factors for Acute Coronary Syndrome in a Large-Scale Replication Study JAMA, April 11, 2007; 297(14): 1551 - 1561. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Zwicker, F. Peyvandi, R. Palla, R. Lombardi, M. T. Canciani, A. Cairo, D. Ardissino, L. Bernardinelli, K. A. Bauer, J. Lawler, et al. The thrombospondin-1 N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size Blood, August 15, 2006; 108(4): 1280 - 1283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B.-l. A. Hannah, T. M. Misenheimer, M. M. Pranghofer, and D. F. Mosher A Polymorphism in Thrombospondin-1 Associated with Familial Premature Coronary Artery Disease Alters Ca2+ Binding J. Biol. Chem., December 10, 2004; 279(50): 51915 - 51922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Cui, E. Randell, J. Renouf, G. Sun, F.-Y. Han, B. Younghusband, and Y.-G. Xie Gender Dependent Association of Thrombospondin-4 A387P Polymorphism With Myocardial Infarction Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): e183 - e184. [Full Text] [PDF]
|
|
|
|
|
|
N. V. Narizhneva, V. J. Byers-Ward, M. J. Quinn, F. J. Zidar, E. F. Plow, E. J. Topol, and T. V. Byzova Molecular and Functional Differences Induced in Thrombospondin-1 by the Single Nucleotide Polymorphism Associated with the Risk of Premature, Familial Myocardial Infarction J. Biol. Chem., May 14, 2004; 279(20): 21651 - 21657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J J McCarthy, A Parker, R Salem, D J Moliterno, Q Wang, E F Plow, S Rao, G Shen, W J Rogers, L K Newby, et al. Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes J. Med. Genet., May 1, 2004; 41(5): 334 - 341. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||